BenevolentAI

Founded: 2013 · London, United Kingdom · 51-200 employees · Private

About BenevolentAI

BenevolentAI is a clinical-stage AI-enabled drug discovery company that uses artificial intelligence and machine learning to decipher complex disease biology and discover optimum therapeutic interventions. Their proprietary Benevolent Platform leverages extracted and deduced biomedical information to design and develop new treatments for patients, with an in-house pipeline of over 20 drug programmes.

Company Details

Website: https://www.benevolent.com
Funding: Acquired
Total Raised: $550M
LinkedIn: https://www.linkedin.com/company/benevolentai
GitHub: https://github.com/BenevolentAI

Specializations

AI/ML
Drug Discovery
Biotechnology
Life Sciences
Pharmaceuticals

Products & Solutions (2)

Product	Category	Sub-Category	Description
BenevolentAI Platform	research-development	Drug Discovery AI	AI-driven target identification and drug discovery
Knowledge Exploration Tools	research-development	Research Discovery	Empowering life scientists with AI-driven insights for higher-confidence decisions and improved R&D productivity.

Notable Customers

AstraZeneca
Merck KGaA